



Office of the Director
Bureau of Competition

UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
WASHINGTON, D.C. 20580

AUG 24 2010

Paul W. Bartel, II, Esquire
Davis Polk & Wardwell LLP
450 Lexington Ave
New York, NY 10017

Re: Charles River Laboratories International, Inc. / WuXi PharmaTech (Cayman) Inc.,
FTC File No. 101-0143

Dear Mr. Bartel:

The Federal Trade Commission's Bureau of Competition has been conducting a nonpublic investigation to determine whether Charles River Laboratories International, Inc.'s acquisition of WuXi PharmaTech (Cayman) Inc. may violate Section 7 of the Clayton Act or Section 5 of the Federal Trade Commission Act.

On July 30, 2010, the Bureau of Competition learned that the parties had abandoned the proposed transaction. Based upon this information, it now appears that no further action is warranted by the Commission at this time. This action is not to be construed as a determination that a violation may not have occurred, just as the pendency of an investigation should not be construed as a determination that a violation has occurred. The Commission reserves the right to take such further action as the public interest may require.

Sincerely yours,

Richard A. Feinstein
Director